Ancillare, LP, a global clinical and ancillary supply chain provider for pharma and biopharma, as well as contract and medical research organizations, was granted a Wholesale Distribution Authorization (WDA) for Human use by the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA).

This will allow Ancillare to continue to support study sponsors’ European needs, regardless of uncertainty about Brexit’s impact on pharmaceutical supply chains. The licensure is critical for study sponsors in the UK market and is a vital link in complex, global clinical trial portfolios and supply chains.

The company plans to add staff at its UK office in order to drive global expansion efforts throughout Europe, the Middle East, Africa and Asia-Pacific.

“I think the license is a testament to the integrity and dedication of our global team,” said Joanne Santomauro, chief executive officer, Ancillare. “No matter how rapidly or exponentially things have changed on the global stage, we’ll always be ready to respond in service to our sponsors.”

Ancillare received the license following an intensive evaluation, auditing and inspections process. Among the qualifying criteria for the license was that Ancillare was in full compliance with the 2012 Human Medicines Regulations, and with the requirements of Good Distribution Practice (GDP). Ancillare’s WDA will enable ongoing wholesaling and distribution activities-including procurement, holding, supply and export-from its European regional office and master depot in Milton Keynes.